Nigel L. Webb, PhD
President and Chief Executive Officer, Board Member
During his career in the pharmaceutical industry, Nigel Webb has pioneered a wide range of breakthrough therapies and clinical diagnostics using small molecules, nucleic acids and monoclonal antibodies. Dr. Webb co-invented a new cancer drug and directed its development from discovery through FDA-compliant Phase III clinical studies in four countries, while leading research collaborations with the Johns Hopkins Medical School and the National Cancer Institute. He is an inventor on eleven issued US drug patents. Before founding RiboNova, Dr. Webb started three biotechnology firms, two of which became publicly-traded companies. He held senior management positions with the pharmaceutical companies Searle and Johnson & Johnson, and he served on the boards of five other biomedical companies. Dr. Webb has negotiated multinational licensing agreements, conducted public offerings and arranged many private financings. He has served on the boards of the Massachusetts state biotechnology center and the United States biotechnology trade association. Since Dr. Webb founded RiboNova, the National Institutes of Health has awarded Dr. Webb four peer-reviewed grants for his medical research into potential therapeutic applications of nucleic acid modifications. Dr. Webb was trained as a molecular biologist at the University of Cambridge and the Medical Research Council in the UK, where he studied transfer RNA in the laboratory of DNA Nobel laureate Maurice Wilkins. He received his MA in biochemistry with first class honours from the University of Cambridge, his PhD in biophysics from the University of London, his CDipAF in finance from the UK Association of Certified Accountants, and he completed the Executive Program at the Harvard Business School.